I don’t care what the ‘health experts’ say. Drinking a beer, smoking a cigarette, playing cards, and socializing is healthy

Kann mir jemand was zur Ernährung während einer Chemotherapie erzählen? Auf was muss man achten, was tut gut? Was ist verträglich? Hat jemand Erfahrungen?

AIDS WAR DER ERSTE GROẞE BETRUG! Mit irrelevanten Testergebnissen hat man Menschen Angst gemacht und diskriminiert. Durch angeblich präventive Medikation mit hochgiftigen Medikamenten hat man Tausende in aller Welt krank gemacht und getötet. Hätte ich bloß Peter Duesberg früher gehört! Es tut mir sehr Leid! youtube.com/watch?v=W_ps3zYY…

My boyfriend suddenly became obsessed with going to the gym. New clothes. New haircut. New confidence. I thought he was preparing to leave me. One day I asked why he'd changed. He looked embarrassed. Then admitted: "One kid called me 'uncle' last month."

Der Nachruf auf unsere Heike Matthiesen hat ein liebes Update bekommen: Emma Rush hat ihr von Annette Kruisbrink gewidmetes Stück "The tall grass bends to listen" als Tribut an Heike eingespielt. Ihr könnt es über diesen Link oder bei YT genießen 🕯️ archiv-frau-musik.de/archive…

#ASCO26 This one is special. This is the hottest paper of 2026 and potentially in the history of pancreatic cancer. Let’s dive in. RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer Abstract LBA5 (soon!) Presentation: May 31, 2026, 3:21-3:33 PM CDT For decades, pancreatic cancer has been where good ideas go to die. We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains. But the central driver of PDAC has always been sitting there in plain sight: RAS. More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it. Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS. And in RASolute 302, it delivered. Quick hits: 📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy 🧬 RAS G12 population 91.8% of patients had RAS G12 mutations 📈 OS in RAS G12 population 13.2 vs 6.6 months HR 0.40 P<0.001 📈 OS in overall population 13.2 vs 6.7 months HR 0.40 P<0.001 📊 PFS in RAS G12 population 7.3 vs 3.5 months HR 0.45 P<0.001 📊 PFS in overall population 7.2 vs 3.6 months HR 0.49 P<0.001 🔥 12-month OS Overall population: 53.2% vs 17.3% ⚠️ Toxicity matters, but this was not just more efficacy for more toxicity Grade ≥3 AEs: 61.8% vs 69.6% TRAEs leading to discontinuation: 1.2% vs 11.2% This is the kind of survival curve we almost never get to see in pancreatic cancer. This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial. The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone. RAS is here, and it couldn’t have come sooner. nejm.org/doi/full/10.1056/NE… @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO @NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc

a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed's breakthru in the fight against pancreatic cancer. u never forget these moments. it's what innovation is all about.

The most important paper of #ASCO26 just dropped in Nature Med! Or any other @asco or @myESMO meetings to be honest. When you hear someone present “the toxicities were acceptable”, please respond “downplaying toxicities is not acceptable”. Thank you @NatureMedicine for publishing this piece. nature.com/articles/s41591-0…

One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

Hab so Bock auf die Fussball WM, 1500 Dollar Eintritt für Curacao gegen die Elfenbeinküste, ein Stürmer der französischen Nationalmannschaft wird von ICE inhaftiert und auf der Eröffnungsfeier opfert Gianni Infantino einen mexikanischen Gastarbeiter auf einem Berg von Geldkoffern